EUVIMED · CrossrefJournal
Nucleic Acid Therapeutics
ISSN 2159-3337 · SAGE Publications
Latest articles
Improved Efficacy and Tolerability of Antisense Oligonucleotide with Guanidine-Bridged Nucleic Acid
Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies
Exploring Clearance Pathways for GalNAc–siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium
Cryopreservation of siRNA-Treated Cells Is Feasible
Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection
Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2′- O -Methoxyethyl Modifications for Intracellular Trafficking and Biodistribution Studies
Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid
Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs
Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations
Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry Survey
Addressing the Challenges of Treating Patients with Heterozygous Gain of Function Mutations
Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome
Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients
Rapid and Reliable Quantification of Prime Editing Targeting Within the Porcine ABCA4 Gene Using a BRET-Based Sensor
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products
Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia
Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat
Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells
Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab Cells
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs
EUVIMED